Disc Medicine (IRON) Projected to Post Earnings on Thursday

Disc Medicine (NASDAQ:IRON) is anticipated to post its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of ($1.71) per share for the quarter. Investors may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Friday, March 6, 2026 at 9:30 AM ET.

Disc Medicine Trading Up 4.3%

Shares of Disc Medicine stock opened at $64.00 on Tuesday. The firm’s 50 day simple moving average is $76.07 and its two-hundred day simple moving average is $75.40. The firm has a market capitalization of $2.42 billion, a price-to-earnings ratio of -11.96 and a beta of 0.88. Disc Medicine has a 12-month low of $30.82 and a 12-month high of $99.50. The company has a current ratio of 23.45, a quick ratio of 23.45 and a debt-to-equity ratio of 0.05.

Analysts Set New Price Targets

IRON has been the subject of a number of recent analyst reports. Stifel Nicolaus cut their price objective on Disc Medicine from $125.00 to $110.00 and set a “buy” rating for the company in a research report on Tuesday, February 17th. Wedbush cut their price target on shares of Disc Medicine from $110.00 to $88.00 and set an “outperform” rating for the company in a report on Tuesday, February 17th. Raymond James Financial reaffirmed a “market perform” rating on shares of Disc Medicine in a report on Thursday, January 15th. Morgan Stanley set a $75.00 target price on shares of Disc Medicine in a research report on Tuesday, February 17th. Finally, Cantor Fitzgerald reduced their price target on shares of Disc Medicine from $153.00 to $125.00 and set an “overweight” rating for the company in a research report on Tuesday, February 17th. Eleven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $104.82.

Insider Transactions at Disc Medicine

In related news, insider William Jacob Savage sold 3,256 shares of Disc Medicine stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $62.86, for a total value of $204,672.16. Following the completion of the transaction, the insider owned 92,589 shares in the company, valued at approximately $5,820,144.54. The trade was a 3.40% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Pamela Stephenson sold 5,531 shares of the stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $62.86, for a total transaction of $347,678.66. Following the completion of the transaction, the insider owned 80,998 shares in the company, valued at $5,091,534.28. This represents a 6.39% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 284,761 shares of company stock worth $24,913,484. 3.64% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Disc Medicine

Several hedge funds and other institutional investors have recently bought and sold shares of IRON. Persistent Asset Partners Ltd purchased a new stake in Disc Medicine in the fourth quarter valued at $141,000. Russell Investments Group Ltd. increased its position in shares of Disc Medicine by 15,137.5% during the third quarter. Russell Investments Group Ltd. now owns 2,438 shares of the company’s stock worth $161,000 after purchasing an additional 2,422 shares in the last quarter. Tower Research Capital LLC TRC lifted its holdings in shares of Disc Medicine by 383.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 3,975 shares of the company’s stock valued at $211,000 after purchasing an additional 3,152 shares during the last quarter. Virtus Investment Advisers LLC lifted its holdings in shares of Disc Medicine by 34.2% in the 4th quarter. Virtus Investment Advisers LLC now owns 2,897 shares of the company’s stock valued at $230,000 after purchasing an additional 739 shares during the last quarter. Finally, AlphaCentric Advisors LLC acquired a new stake in shares of Disc Medicine in the 4th quarter valued at about $298,000. 83.70% of the stock is currently owned by institutional investors and hedge funds.

Disc Medicine Company Profile

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.